KTTA (Pasithea Therapeutics) Tariff Resilience Score: 7/10 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KTTA Pasithea Therapeutics Corp KTTA
29 GF Score
Price $0.45
! 2 Warning Signs
View Full Analysis

What is Pasithea Therapeutics Tariff Resilience Score?

Pasithea Therapeutics KTTA -3.89% 29 Tariff Resilience Score is 7 as of Jul. 21, 2026. GuruFocus rates KTTA with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,370 Biotechnology companies, Pasithea Therapeutics ranks better than 90.36% on this metric.

Pasithea Therapeutics has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Pasithea Therapeutics has Pasithea Therapeutics has limited direct exposure to tariffs, as its operations are primarily focused on domestic markets. However, its supply chain for pharmaceuticals may face some vulnerabilities.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Pasithea Therapeutics might have Highly Resilient.

Pasithea Therapeutics  (NAS:KTTA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Pasithea Therapeutics Tariff Resilience Score Related Terms

KTTA vs CELU, GRTX, BCDA: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Pasithea Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pasithea Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pasithea Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Pasithea Therapeutics's Tariff Resilience Score falls into.


KTTA
29GF Score
Pasithea Therapeutics Corp KTTA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Pasithea Therapeutics (KTTA) has a Tariff Resilience Score of 7 as of Jul. 21, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Pasithea Therapeutics ranks #132 out of 1370 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Pasithea Therapeutics' Tariff Resilience Score too high?
Pasithea Therapeutics' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Pasithea Therapeutics' value of 7 is 75% above this industry median. Based on the distribution chart, Pasithea Therapeutics ranks #132 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pasithea Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Pasithea Therapeutics' Tariff Resilience Score compare to CELU and GRTX?
According to the Biotechnology industry distribution chart, Pasithea Therapeutics ranks #132 out of 1370 companies for Tariff Resilience Score. This places Pasithea Therapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Pasithea Therapeutics' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pasithea Therapeutics's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pasithea Therapeutics's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pasithea Therapeutics stock overvalued right now?
Pasithea Therapeutics (KTTA) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Pasithea Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Pasithea Therapeutics (KTTA), the current Tariff Resilience Score is 7 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pasithea Therapeutics Business Description

Address 1111 Lincoln Road, Suite 500, Miami Beach, FL, USA, 33139
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
29GF Score

Get the complete analysis for KTTA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.45
Price